Table 1.
Baseline patient characteristics
| Scalp IGA ≥ 3 (N = 821) |
mNAPSI > 10 (N = 377) |
Palmoplantar IGA ≥ 3 (N = 193) |
||||
|---|---|---|---|---|---|---|
| BKZ total (N = 821) |
BKZ Q4W/Q8W (n = 277) |
BKZ total (N = 377) |
BKZ Q4W/Q8W (n = 129) |
BKZ total (N = 193) |
BKZ Q4W/Q8W (n = 52) |
|
| Age (years), mean ± SD | 44.8 ± 13.7 | 44.0 ± 13.9 | 44.8 ± 13.1 | 44.5 ± 13.2 | 45.0 ± 12.9 | 43.8 ± 11.5 |
| Male, n (%) | 569 (69.3) | 192 (69.3) | 316 (83.8) | 107 (82.9) | 144 (74.6) | 41 (78.8) |
| White, n (%) | 715 (87.1) | 259 (93.5) | 328 (87.0) | 123 (95.3) | 162 (83.9) | 49 (94.2) |
| Weight (kg), mean ± SD | 89.8 ± 21.4 | 88.8 ± 21.0 | 92.2 ± 20.7 | 92.1 ± 20.6 | 85.9 ± 18.7 | 87.0 ± 17.4 |
| Duration of psoriasis (years), mean ± SD | 18.1 ± 12.6 | 18.6 ± 12.4 | 18.9 ± 12.4 | 18.8 ± 12.2 | 17.7 ± 12.1 | 18.8 ± 9.8 |
| PsA status, n (%) | ||||||
| PASE ≥ 47 | 131 (16.0) | 36 (13.0) | 80 (21.2) | 25 (19.4) | 38 (19.7) | 6 (11.5) |
| Reported history of PsA | 194 (23.6) | 53 (19.1) | 107 (28.4) | 31 (24.0) | 54 (28.0) | 8 (15.4) |
| Either PASE ≥ 47 or reported history of PsA | 194 (23.6) | 53 (19.1) | 107 (28.4) | 31 (24.0) | 54 (28.0) | 8 (15.4) |
| PASI, mean ± SD | 21.4 ± 8.0 | 20.9 ± 7.7 | 22.4 ± 8.5 | 21.6 ± 8.0 | 23.9 ± 9.0 | 26.9 ± 10.6 |
| BSA (%), mean ± SD | 26.6 ± 16.0 | 24.5 ± 13.5 | 28.9 ± 17.6 | 25.7 ± 13.8 | 30.5 ± 17.4 | 31.6 ± 15.6 |
| IGA score, n (%) | ||||||
| 3: moderate | 527 (64.2) | 189 (68.2) | 212 (56.2) | 75 (58.1) | 109 (56.5) | 24 (46.2) |
| 4: severe | 294 (35.8) | 88 (31.8) | 163 (43.2) | 53 (41.1) | 83 (43.0) | 27 (51.9) |
|
DLQI total score, mean ± SD |
10.8 ± 6.5 | 10.7 ± 6.6 | 10.7 ± 6.6 | 11.1 ± 6.0 | 11.3 ± 7.1 | 11.8 ± 7.0 |
|
Scalp IGA score, mean ± SD |
3.2 ± 0.4 | 3.2 ± 0.4 | 2.8 ± 1.0 | 2.8 ± 0.9 | 3.0 ± 0.8 | 3.1 ± 0.7 |
|
mNAPSI score, mean ± SD |
11.6 ± 17.8 | 11.1 ± 16.2 | 31.0 ± 20.5 | 28.2 ± 16.9 | 21.9 ± 28.0 | 22.9 ± 23.7 |
| Pattern of nail involvement, n (%) | ||||||
| Nail matrix | 410 (86.0) | 135 (85.4) | 359 (95.2) | 124 (96.1) | 124 (93.2) | 35 (94.6) |
| Nail bed | 405 (84.9) | 140 (88.6) | 357 (94.7) | 121 (93.8) | 117 (88.0) | 35 (94.6) |
| Palmoplantar IGA score, mean ± SD | 0.9 ± 1.3 | 0.8 ± 1.2 | 1.3 ± 1.4 | 1.1 ± 1.4 | 3.2 ± 0.4 | 3.2 ± 0.4 |
| Any prior systemic therapy, n (%) | 635 (77.3) | 209 (75.5) | 297 (78.8) | 100 (77.5) | 163 (84.5) | 45 (86.5) |
| Any prior biologic therapy, n (%) | 306 (37.3) | 95 (34.3) | 139 (36.9) | 41 (31.8) | 70 (36.3) | 18 (34.6) |
| Anti-TNF | 123 (15.0) | 33 (11.9) | 63 (16.7) | 14 (10.9) | 34 (17.6) | 4 (7.7) |
| Anti-IL-17 | 160 (19.5) | 51 (18.4) | 83 (22.0) | 27 (20.9) | 39 (20.2) | 15 (28.8) |
| Anti-IL-12/23 | 54 (6.6) | 19 (6.9) | 19 (5.0) | 6 (4.7) | 7 (3.6) | 1 (1.9) |
| Anti-IL-23 | 47 (5.7) | 18 (6.5) | 12 (3.2) | 6 (4.7) | 8 (4.1) | 1 (1.9) |
Data are presented for patients with plaque psoriasis initially randomized to bimekizumab (BKZ) who later entered the open-label extension (OLE). In this analysis, BKZ 320 mg every 4 weeks (Q4W) and every 8 weeks (Q8W) treatment arms are pooled for the BKZ total group
BKZ bimekizumab, BSA body surface area, DLQI Dermatology Life Quality Index, IGA Investigator’s Global Assessment, IL interleukin, mNAPSI modified Nail Psoriasis Severity Index, OLE open-label extension, PASE Psoriatic Arthritis Screening and Evaluation, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, Q4W every 4 weeks, Q8W every 8 weeks, SD standard deviation, TNF tumor necrosis factor